Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who were 1 year old or younger, or older than 22 years old, at the time their leukemia came back (confirm with trial site, as this age range is unusual — it may mean between 1 and 22 years old)
• People who have been diagnosed with a specific type of blood cancer called acute lymphoblastic leukemia (ALL), either the B-cell type (B-ALL) or T-cell type (T-ALL)
• People whose leukemia has come back for the first time, and where the relapse involves the bone marrow (relapse in other parts of the body at the same time is also acceptable)
• People who have never had a bone marrow or stem cell transplant from a donor
• People who have never been treated with a drug called blinatumomab before
• People whose kidneys are working well enough, based on a blood test result that falls within acceptable ranges for their age and sex
• People whose liver is working well enough, based on a specific blood test result being below a certain level
• People whose heart is working well enough, as shown by a heart scan (echocardiogram)
• People who are well enough to carry out daily activities, as measured by a standard health scoring tool appropriate for their age
• People with a life expectancy of at least one year
• People who are expected to be able to follow all study procedures and requirements, in the opinion of the study doctor
• People (or their guardians) who have signed a consent form before any study procedures begin

Who may not be able to join:

• People with a type of leukemia called Burkitt leukemia/lymphoma or mature B-cell leukemia
• People whose leukemia has a specific genetic marker called Philadelphia chromosome positive (Ph+)
• People with B-cell leukemia whose cancer cells do not carry a protein called CD19, as detected by a laboratory test — the trial site would not be able to administer blinatumomab in these cases
• People whose leukemia came back within one month of finishing an initial treatment course using the same four-drug combination used in this study
• People with a type of leukemia that has mixed features (called mixed phenotype leukemia)
• People who have certain inherited genetic conditions, including Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other bone marrow failure syndromes
• People who are known to have HIV
• Female patients who are pregnant, or who cannot confirm they are not pregnant (confirmed through a urine test, medical history, or evidence of infertility or menopause)
• People currently taking part in another clinical trial involving an experimental drug
• People with unstable health conditions that could put them at risk or affect their ability to follow the study requirements
• People with serious nervous system or brain conditions, such as uncontrolled seizures, paralysis, speech difficulties, a history of severe brain injury, certain brain diseases, psychosis, or significant movement or coordination problems
• People with a known allergy or serious reaction to any of the drugs used in this study: Idarubicin, Etoposide, Ifosfamide, Cytarabine, Vincristine, Mercaptopurine, or Blinatumomab

Important: Always verify eligibility with the trial site directly before applying.